跳至主要内容
临床试验/EUCTR2018-002264-57-DE
EUCTR2018-002264-57-DE进行中(未招募)1 期

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis - Heads UP

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 650 人开始时间: 2019年2月27日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
650

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male or female subjects between 18 years old and 75 years old
  • Active moderate to severe atopic dermatitis defined by EASI, IGA, BSA, and pruritus
  • Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 600
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • Prior exposure to any JAK inhibitor or Dupilumab
  • Unable or unwilling to discontinue current AD treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study

研究者

相似试验